Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Research

International Salmonella Typhimurium DT104 Infections, 1992–2001

Morten Helms*Comments to Author , Steen Ethelberg*, Kåre Mølbak*, and the DT104 study group
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark

Main Article

Table 1

Number of patients with culture-confirmed, nontyphoidal Salmonella infection and percentage S. Typhimurium, international DT104 survey, 1992–2001

Subregion/country Nontyphoidal Salmonella infections (% S. Typhimurium)
1992–1993 1994–1995 1996–1997 1998–1999 2000–2001 2001 pop. (IST)*
Northern Europe
England + Wales 62,005 (16.4) 59,725 (20.5) 61,579 (16.8) 41,260 (13.2) 31,309 (15.1) 53 (3.9)
Ireland 1,152 (65.6) 1,147 (36.5) 3.8 (3.9)
Scotland 5,911 (20.1) 6,076 (21.6) 6,615 (19.8) 3,988 (16.0) 3,291 (17.8) 5.1 (5.0)
Denmark 7,184 (34.5) 7,923 (28.0) 8,273 (21.1) 7,148 (17.7) 5,257 (19.5) 5.4 (10.9)
Finland† 6,770 (13.0) 6,070 (14.1) 5,615 (16.9) 5,536 (12.4) 5,358 (10.4) 5.2 (5.0)
Latvia 1,048 (54.2) 1,965 (41.9) 1,393 (29.0) 1,830 (23.1) 1,664 (9.3) 2.4 (2.8)
Norway† 2,181 (18.1) 2,386 (13.3) 2,632 (16.4) 2,933 (14.9) 3,394 (13.5) 4.5 (4.9)
Sweden† 5,296 (17.5) 11,249 (13.3) 10,479 (11.5) 11,398 (13.8) 11,119 (14.1) 8.9 (8.3)
Western Europe
Austria 11,337 (10.0) 19,790 (5.5) 18,278 (5.2) 16,918 (4.7) 15,135 (5.6) 8.3 (5.6)
Belgium 21,231 (34.7) 22,048 (31.9) 26,247 (26.2) 30,288 (21.7) 25,153 (20.6) 10.3 (23.0)
Germany‡ 335,813 (17.1) 248,507 (21.9) 215,524 (26.4) 183,697 (27.1) 163,327 (26.2) 82.2 (8.4)
Luxembourg 490 (27.8) 447 (17.4) 555 (22.5) 652 (22.9) 701 (23.8) 0.44 (19.8)
Netherlands 5,388 (36.2) 5,955 (26.2) 5,445 (32.8) 4,393 (31.1) 4,141 (31.8) 16.0 (6.9)
Switzerland§ 2,374 (10.2) 7.2
Eastern Europe
Czech Republic 85,097 (6.8) 103,342 (2.6) 88,421 (2.3) 95,323 (2.1) 73,529 (1.9) 10.3 (5.3)
Hungary 14,138 (15.0) 11,398 (12.6) 8,188 (20.2) 8,480 (10.7) 10.0 (5.5)
Southern Europe
Greece 1,198 (13.4) 1,514 (14.5) 1,315 (18.2) 1,091 (24.3) 1,947 (20.5) 10.9 (13.4)
Malta 546 (20.1) 518 (26.6) 236 (19.1) 390 (3.6) 135 (34.8) 0.40 (9.0)
Spain¶ 6,374 (25.9) 7,188 (29.0) 8,847 (32.9) 10,806 (25.6) 13,379 (21.1) 39.8 (3.5)
Israel# 15,337 (10.7) 13,674 (8.1) 10,168 (27.2) 9,875 (16.8) 9,353 (15.0) 6.4 (11.4)
North America
Canada 14,863 (19.2) 13,645 (20.3) 14,596 (23.0) 16,028 (21.0 12,493 (20.9) 31.0 (4.9)
USA 71,605 (22.6) 78,723 (22.5) 73,643 (25.3) 66,753 (25.3) 63,697 (22.1) 281.4 (2.6)
Caribbean region 687 (22.1) 786 (22.8) 379 (10.6) 7.1 (0.3)
Brazil 2,276 (10.5) 7,500 (2.7) 11,832 (1.5) 10,511 (3.8) 15,455 (4.8) 171.8 (0.3)
South Africa 1,341 (51.3) 43.6 (1.2)
Eastern Asia
Japan 18,385 (8.4) 22,406 (6.1) 27,260 (2.8) 23,359 (3.2) 11,889 (5.3) 127.4 (0.2)
Republic of Korea 1,918 (37.4) 1,567 (32.0) 2,314 (18.7) 3,548 (15.9) 2,404 (11.3) 48.8 (0.3)
Oceania
Australia 9,496 (28.1) 11,794 (35.2) 13,229 (40.2) 15,104 (35.2) 13,053 (38.9) 19.4 (13.7)
New Zealand 2,579 (56.2) 3,137 (58.3) 2,658 (56.6) 4,472 (63.1) 4,517 (64.7 3.9 (42.7)

*pop., population ×106; IST, incidence of S. Typhimurium per 105 population.
†Most patients in these countries were infected abroad.
‡Data on S. Typhimurium and incidence are based on data from the new federal states of Germany and the city of Berlin.
§Submission of strains for serotyping at the central laboratory was not compulsory in Switzerland at the time of data collection. As a result an incidence rate for Switzerland is not presented.
¶Incidence is based on data from 2000.
#According to the United Nations classification, Israel belongs to the western Asian region. In this study, Israel has been grouped with southern European countries.

Main Article

1Data for this survey were contributed by the DT104 study group, which consisted of the following: Diane Lightfoot and J. Powling, Australia; Christian Berghold and Christian Kornshober, Austria; Ingrid Wybo, J.M. Collard, and C. Godard, Belgium; Dalia dos Prazeres Rodrigues, Eliane Moura Falavina dos Reis, and Erica L. Fonseca, Brazil; Kathryn Doré, James Flint, Frank Pollari, Rafiq Ahmed, and Walter Demczuk, Canada; James Hospedales, Denise Clarke, and Michelle Nurse-Lucas, Caribbean Region; Renata Karpiskova, The Czech Republic; Peter Gerner-Smidt, Denmark; Noël Gill, Sarah O'Brien, and John Threlfall, England and Wales; Anja Siitonen and Susanna Lukinmaa, Finland; Wolfgang Rabsch, Germany; Panayotis T. Tassios, Leonidas S. Tzouvelekis, and Takis Panagiotopoulos, Greece; Judit Pàszti and Noelni Nógrády, Hungary; Barbara Foley, Martin Cormican, and Paul McKeown, Ireland; Nahum Andorn and Ruti Yishai, Israel; Haruo Watanabe and Hidemasa Izumiya, Japan; Bok Kwon Lee and Shukho Kim, Republic of Korea; J. Selga and J. Jansone, Latvia; Joel Mossong and François Schneider, Luxembourg; Julie Haider and Paul Cuschieri, Malta; Wilfrid van Pelt, Netherlands; Helen Heffernan and Carolyn Nicol, New Zealand; Karin Nygård and Trine Lise Stavnes, Norway; B.L. Cherkasskiy, Russian Federation; Lynda Browning and John Coia, Scotland; Karen Helena Keddy and Tersia Kruger, Republic of South Africa; Miquel Anger Usera, Spain; Agneta Olsson, Sweden; Patrick Boerlin, Switzerland; Timothy Barrett, Frederick J. Angulo, and Jennifer E. Stevenson, USA.

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external